Edition:
India

People: Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

32.03USD
16 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$32.03
Open
$31.49
Day's High
$32.60
Day's Low
$31.49
Volume
115,333
Avg. Vol
149,289
52-wk High
$41.59
52-wk Low
$18.00

Mavilio, Fulvio 

Mr. Fulvio Mavilio is Senior Vice President - Translational Science of the Company. Fulvio is a highly regarded, world-leading expert and pioneer in the gene therapy field. He has designed and developed gene therapies for inherited and acquired diseases, including the first ever commercially approved ex vivo gene therapy, Strimvelis ® . Fulvio joined Audentes in 2017 from Genethon where he served as Chief Scientific Officer and led the development of a robust pipeline of gene therapy programs, including the initial discovery work for AT132. Prior to Genethon, Fulvio was co-Director of the Center for Regenerative Medicine of the University of Modena, Director of Discovery of Molmed SpA, founder and Chief Scientific Officer of Genera SpA, and co-Director of the San Raffaele-Telethon Institute of Gene Therapy. Fulvio serves as Professor of Molecular Biology at the University of Modena and Reggio Emilia. He earned an undergraduate degree in Biology at the University of Rome and a Ph.D. in Medical Genetics at the University of Rome School of Medicine.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --